Last Updated : April 30, 2025
Details
| Call for patient/clinician input open | March 23, 2023 |
|---|---|
| Call for patient/clinician input closed | May 15, 2023 |
| Clarification: - Patient input submission received from Alagille Syndrome Alliance and Canadian Liver Foundation | |
| Submission received | May 05, 2023 |
| Submission accepted | May 19, 2023 |
| Review initiated | May 23, 2023 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | August 04, 2023 |
| Deadline for sponsors comments | August 16, 2023 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | September 15, 2023 |
| Expert committee meeting (initial) | September 27, 2023 |
| Draft recommendation issued to sponsor | October 12, 2023 |
| Draft recommendation posted for stakeholder feedback | October 19, 2023 |
| End of feedback period | November 02, 2023 |
| Clarification: - Reconsideration: major revisions requested by sponsor | |
| Expert committee meeting | February 28, 2024 |
| Draft recommendation issued to sponsor | March 11, 2024 |
| Draft recommendation posted for stakeholder feedback | March 21, 2024 |
| End of feedback period | April 08, 2024 |
| Final recommendation issued to sponsor and drug plans | April 22, 2024 |
| Final recommendation posted | May 09, 2024 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | May 07, 2024 |
| Canada's Drug Agency review report(s) posted | September 20, 2024 |